CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

ThalassaX doses first US patient in Phase I study of CS231295

Phase 1CS231295Positive
AI Analysis

Summary

ThalassaX Therapeutics has dosed the first patient in a Phase I trial of CS231295, a brain-penetrant Aurora B kinase selective inhibitor, in the United States.

Clinical Trial Data

Phase

Phase I

Importance:3/10
Sentiment:
0.30
Phase 1clinical trialkinase inhibitorneurology
Related Companies

Read the original article

Published by Clinical Trials Arena on July 20, 2026 10:27 AM

Read Original